194 related articles for article (PubMed ID: 38253025)
1. Proteomic and metabolomic signatures of U87 glioblastoma cells treated with cisplatin and/or paclitaxel.
Ahmed M; Semreen AM; Giddey AD; Ramadan WS; El-Awady R; Soares NC; El-Huneidi W; Bustanji Y; Alqudah MAY; Alzoubi KH; Semreen MH
Ann Med; 2023; 55(2):2305308. PubMed ID: 38253025
[TBL] [Abstract][Full Text] [Related]
2. Albumin-bound paclitaxel augment temozolomide treatment sensitivity of glioblastoma cells by disrupting DNA damage repair and promoting ferroptosis.
Qu S; Qi S; Zhang H; Li Z; Wang K; Zhu T; Ye R; Zhang W; Huang G; Yi GZ
J Exp Clin Cancer Res; 2023 Oct; 42(1):285. PubMed ID: 37891669
[TBL] [Abstract][Full Text] [Related]
3. Metabolomics Analysis Revealed Significant Metabolic Changes in Brain Cancer Cells Treated with Paclitaxel and/or Etoposide.
Semreen AM; Alsoud LO; El-Huneidi W; Ahmed M; Bustanji Y; Abu-Gharbieh E; El-Awady R; Ramadan WS; Alqudah MAY; Shara M; Abuhelwa AY; Soares NC; Semreen MH; Alzoubi KH
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430415
[TBL] [Abstract][Full Text] [Related]
4. miR-519a enhances chemosensitivity and promotes autophagy in glioblastoma by targeting STAT3/Bcl2 signaling pathway.
Li H; Chen L; Li JJ; Zhou Q; Huang A; Liu WW; Wang K; Gao L; Qi ST; Lu YT
J Hematol Oncol; 2018 May; 11(1):70. PubMed ID: 29843746
[TBL] [Abstract][Full Text] [Related]
5. A HIF-independent, CD133-mediated mechanism of cisplatin resistance in glioblastoma cells.
Ahmed EM; Bandopadhyay G; Coyle B; Grabowska A
Cell Oncol (Dordr); 2018 Jun; 41(3):319-328. PubMed ID: 29492900
[TBL] [Abstract][Full Text] [Related]
6. Preclinical and Clinical Applications of Metabolomics and Proteomics in Glioblastoma Research.
Ahmed M; Semreen AM; El-Huneidi W; Bustanji Y; Abu-Gharbieh E; Alqudah MAY; Alhusban A; Shara M; Abuhelwa AY; Soares NC; Semreen MH; Alzoubi KH
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613792
[TBL] [Abstract][Full Text] [Related]
7. BK channels blockage inhibits hypoxia-induced migration and chemoresistance to cisplatin in human glioblastoma cells.
Rosa P; Catacuzzeno L; Sforna L; Mangino G; Carlomagno S; Mincione G; Petrozza V; Ragona G; Franciolini F; Calogero A
J Cell Physiol; 2018 Sep; 233(9):6866-6877. PubMed ID: 29319175
[TBL] [Abstract][Full Text] [Related]
8. Progesterone at high doses reduces the growth of U87 and A172 glioblastoma cells: Proteomic changes regarding metabolism and immunity.
Altinoz MA; Ucal Y; Yilmaz MC; Kiris İ; Ozisik O; Sezerman U; Ozpinar A; Elmaci İ
Cancer Med; 2020 Aug; 9(16):5767-5780. PubMed ID: 32590878
[TBL] [Abstract][Full Text] [Related]
9. Continuous dose-intense temozolomide and cisplatin in recurrent glioblastoma patients.
Wang Y; Kong X; Guo Y; Wang R; Ma W
Medicine (Baltimore); 2017 Mar; 96(10):e6261. PubMed ID: 28272232
[TBL] [Abstract][Full Text] [Related]
10. An overview of glioblastoma multiforme and temozolomide resistance: can LC-MS-based proteomics reveal the fundamental mechanism of temozolomide resistance?
Teraiya M; Perreault H; Chen VC
Front Oncol; 2023; 13():1166207. PubMed ID: 37182181
[TBL] [Abstract][Full Text] [Related]
11. Identification of potential glioma drug resistance target proteins based on ultra-performance liquid chromatography-mass spectrometry differential proteomics.
Li D; Yan J; Li K; Yang Q; Bian L; Lin B; Liu X; Xi Z
PeerJ; 2023; 11():e16426. PubMed ID: 38054015
[TBL] [Abstract][Full Text] [Related]
12. Modulating Wnt/β-Catenin Signaling Pathway on U251 and T98G Glioblastoma Cell Lines Using a Combination of Paclitaxel and Temozolomide, A Molecular Docking Simulations and Gene Expression Study.
Jamalpour S; Alinezhad A; Sabah JT; Vazifehmand R; Behrooz AB; Hamzah ASA; Davazdahemami AA; Homaie FM; Maddah SM
Chem Pharm Bull (Tokyo); 2023; 71(10):766-774. PubMed ID: 37779078
[TBL] [Abstract][Full Text] [Related]
13. Synergistic drug combinations for a precision medicine approach to interstitial glioblastoma therapy.
Graham-Gurysh EG; Murthy AB; Moore KM; Hingtgen SD; Bachelder EM; Ainslie KM
J Control Release; 2020 Jul; 323():282-292. PubMed ID: 32335153
[TBL] [Abstract][Full Text] [Related]
14. Study on Therapeutic Action and Mechanism of TMZ Combined with RITA Against Glioblastoma.
Wu Q; Cao Z; Xiao W; Zhu L; Xie Q; Li L; Zhang B; Zhao W
Cell Physiol Biochem; 2018; 51(6):2536-2546. PubMed ID: 30562758
[TBL] [Abstract][Full Text] [Related]
15. LINC00511 facilitates Temozolomide resistance of glioblastoma cells via sponging miR-126-5p and activating Wnt/β-catenin signaling.
Lu Y; Tian M; Liu J; Wang K
J Biochem Mol Toxicol; 2021 Sep; 35(9):e22848. PubMed ID: 34328678
[TBL] [Abstract][Full Text] [Related]
16. Revisiting Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients with Glioblastoma-Proteomic Alteration and Comparison Analysis with the Standard-of-Care Chemoirradiation.
Krauze AV; Zhao Y; Li MC; Shih J; Jiang W; Tasci E; Cooley Zgela T; Sproull M; Mackey M; Shankavaram U; Tofilon P; Camphausen K
Biomolecules; 2023 Oct; 13(10):. PubMed ID: 37892181
[TBL] [Abstract][Full Text] [Related]
17. Repurposing an Antiepileptic Drug for the Treatment of Glioblastoma.
Yadav A; Alnakhli A; Vemana HP; Bhutkar S; Muth A; Dukhande VV
Pharm Res; 2022 Nov; 39(11):2871-2883. PubMed ID: 36195821
[TBL] [Abstract][Full Text] [Related]
18. Quantitative Proteomics Analysis Reveals Nuclear Perturbation in Human Glioma U87 Cells treated with Temozolomide.
Guo J; Yi GZ; Liu Z; Sun X; Yang R; Guo M; Li Y; Li K; Li K; Wang X; Song H; Qi S; Huang G; Liu Y
Cell Biochem Funct; 2020 Mar; 38(2):185-194. PubMed ID: 31833081
[TBL] [Abstract][Full Text] [Related]
19. Glioblastoma entities express subtle differences in molecular composition and response to treatment.
Balça-Silva J; Matias D; Do Carmo A; Dubois LG; Gonçalves AC; Girão H; Canedo NHS; Correia AH; De Souza JM; Sarmento-Ribeiro AB; Lopes MC; Moura-Neto V
Oncol Rep; 2017 Sep; 38(3):1341-1352. PubMed ID: 28714013
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
